Globe Life (GL) Expected to Announce Earnings on Wednesday
by Scott Moore · The Cerbat GemGlobe Life (NYSE:GL – Get Free Report) is anticipated to release its Q1 2026 results after the market closes on Wednesday, April 22nd. Analysts expect Globe Life to post earnings of $3.49 per share and revenue of $1.5571 billion for the quarter. Globe Life has set its FY 2026 guidance at 14.950-15.650 EPS. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, April 23, 2026 at 11:00 AM ET.
Globe Life (NYSE:GL – Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $3.39 earnings per share for the quarter, missing the consensus estimate of $3.44 by ($0.05). Globe Life had a return on equity of 21.30% and a net margin of 19.37%.The firm had revenue of $1.52 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period last year, the business posted $3.14 EPS. The company’s revenue was up 3.6% compared to the same quarter last year. On average, analysts expect Globe Life to post $14 EPS for the current fiscal year and $15 EPS for the next fiscal year.
Globe Life Trading Down 0.0%
Shares of GL opened at $151.79 on Monday. The business has a 50-day moving average of $142.79 and a 200 day moving average of $139.02. Globe Life has a fifty-two week low of $111.13 and a fifty-two week high of $152.71. The firm has a market cap of $11.91 billion, a P/E ratio of 10.78 and a beta of 0.47. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.07 and a current ratio of 0.07.
Globe Life Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Friday, April 3rd will be issued a $0.33 dividend. This is an increase from Globe Life’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $1.32 annualized dividend and a yield of 0.9%. Globe Life’s payout ratio is 9.38%.
Analyst Ratings Changes
Several brokerages recently weighed in on GL. Evercore set a $157.00 price objective on Globe Life in a report on Wednesday, February 18th. Wells Fargo & Company raised their target price on Globe Life from $171.00 to $172.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Weiss Ratings upgraded Globe Life from a “hold (c+)” rating to a “buy (b)” rating in a research note on Monday, April 13th. JPMorgan Chase & Co. raised their target price on Globe Life from $180.00 to $181.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Keefe, Bruyette & Woods restated a “moderate buy” rating and issued a $168.00 target price on shares of Globe Life in a research note on Thursday, March 26th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $172.11.
Get Our Latest Analysis on Globe Life
Insiders Place Their Bets
In other Globe Life news, CMO Jennifer Allison Haworth sold 10,000 shares of the firm’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $143.14, for a total value of $1,431,400.00. Following the completion of the transaction, the chief marketing officer owned 17,479 shares in the company, valued at $2,501,944.06. This trade represents a 36.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Clay Majors sold 30,000 shares of Globe Life stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $146.89, for a total value of $4,406,700.00. Following the sale, the executive vice president owned 47,066 shares of the company’s stock, valued at approximately $6,913,524.74. This trade represents a 38.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 82,807 shares of company stock worth $12,041,286 over the last quarter. Insiders own 2.11% of the company’s stock.
Institutional Trading of Globe Life
Large investors have recently modified their holdings of the business. CYBER HORNET ETFs LLC bought a new stake in shares of Globe Life during the 2nd quarter valued at about $28,000. MUFG Securities EMEA plc bought a new stake in shares of Globe Life during the 2nd quarter valued at about $31,000. Banque Cantonale Vaudoise bought a new stake in shares of Globe Life during the 3rd quarter valued at about $50,000. Summit Securities Group LLC boosted its position in shares of Globe Life by 203.6% during the 4th quarter. Summit Securities Group LLC now owns 422 shares of the company’s stock valued at $59,000 after acquiring an additional 283 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its position in shares of Globe Life by 105.6% during the 4th quarter. Brown Brothers Harriman & Co. now owns 477 shares of the company’s stock valued at $67,000 after acquiring an additional 245 shares during the last quarter. Institutional investors own 81.61% of the company’s stock.
About Globe Life
Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.
The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.